FMR1 and prostate carcinoma: This m6A-mediated interaction not only sustains mitochondrial metabolism but also impedes the heightened efficacy of androgen receptor signaling inhibitors, like enzalutamide and darolutamide, suggesting a mechanism by which FMRP contributes to prostate cancer progression and therapeutic resistance.